step 1 trial semaglutide 2.4 mg weight loss nejm 2021 FDA Approves As An Powerful Weight-loss Drug For patients with #obesity, semaglutide,

Months 46: Momentum Builds This is when the magic really happens

GLP-1 RAs are not renally cleared and do not require dose adjustment for hepatic impairment per se

Given that PKC and TRPM5 are downstream effectors of Gq signalling in beta cells, our next step involved determining whether the PKC inhibitor (calphostin C) and TRPM5 blocker (TPPO) suppress the triagonist-induced increase in GSIS

There's a diabetes tie-in, of course, but if you just want to know about the episode feel free to scroll down

Clinical research shows that some patients may start to see weight loss within the first few weeks

Its also about implementing healthy habits so I try to focus on that instead